Efficacy of intra-arterial chemotherapy across intracranial tumors: A systematic review and meta-analysis
Current evidence supports the role of IAC in ocular retinoblastoma. For gliomas, HNSCC and other skull-base tumors, IAC remains investigational where survival benefit over systemic therapy is unproven. Generally, the pharmacologic advantages of IA delivery alone have not translated into a consistent survival benefit outside retinoblastoma.
Authors
- Elham Rahmanipour (ORCID: https://orcid.org/0000-0001-8454-458X)
- Enes Demir (ORCID: https://orcid.org/0000-0003-0950-7740)
- Mahyar Daskareh (ORCID: https://orcid.org/0000-0001-5601-6392)
- Mehrdad Pahlevani (ORCID: https://orcid.org/0009-0001-4275-261X)
- Denise Baloi (ORCID: https://orcid.org/0009-0007-8780-2581)
- Golnaz Golrokhian Sani
- Khushal Gupta
- Curtis Patillo
- Sina Samieirad
- Michael Karsy
- Mohammad Ghorbani
Institutions
- Mashhad University of Medical Sciences (IR)
- Pt. Jawahar Lal Nehru Memorial Medical College (IN)
- Jamaica Hospital (US)
- Michigan Medicine (US)
- Eskişehir Osmangazi University (TR)
- University of Pennsylvania (US)
- The University of Texas at Austin (US)
- Michigan State University (US)
Publication Details
- Journal
- Critical Reviews in Oncology/Hematology
- Published
- 2026-02-10
- DOI
- https://doi.org/10.1016/j.critrevonc.2026.105210
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00